Business
Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification
Backed by an Exclusive 20-Year McMaster University License, Triera Targets High-Priority Infectio...
About this update from Zentek Ltd.
[{"type":"text","content":"Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning ClassificationBacked by an Exclusive 20-Year McMaster University License, Triera Targets High-Priority Infectious Disease and Oncology Detection Markets Across Canada, the United States, and Europe GUELPH, ON / ACCESS Newswire / March 25, 2026 / Zentek Ltd. (TSXV:ZEN)(NASDAQ:ZTEK) (\"Zentek\" or the \"Company\") announces that its wholly-owned subsidiary, Triera Biosciences Ltd. (\"Triera\"), plans to begin offering contract research organization (\"CRO\") services for custom aptamer discovery, biosensor enablement, and machine-learning (\"ML\") classification support to pharmaceutical, biotechnology, and diagnostics organizations in Canada, the United States, Europe, and other markets that require high-performance molecular recognition tools but do not have in-house SELEX expertise, biosensor engineering capability, or ML classification systems to develop them.A Differentiated Platform Built on Deep ScienceTriera's aptamer discovery capabilities were developed in collaboration with Dr. Yingfu Li's research team at McMaster University, a globally recognized leader in functional nucleic acid chemistry and SELEX methodology. Triera holds an exclusive, worldwide, royalty-bearing license from McMaster University to use and practice aptamer applications developed through this collaboration for the next 20 years: a durable scientific foundation the Company believes represents a meaningful competitive position in the CRO services landscape.What distinguishes Triera's CRO model is its integration of three capabilities within a single engagement: (i) custom aptamer discovery and optimization via SELEX, (ii) biosensor engineering and integration support, and (iii) optional ML classification systems for signal interpretation. Aptamers are chemically synthesized, enabling consistent batch-to-batch production, rapid iteration, and defined stability profiles - structural advantages over antibody-based molecular recognition tools in certain diagnostic and sensing applications.Triera's current catalogue contains aptamers for clinically and commercially significant targets including influenza A, SARS-CoV-2, vascular endothelial growth factor (VEGF, a solid tumour biomarker), syphilis, n...